Concepedia

Publication | Closed Access

Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies.

DOI

61

Citations

9

References

1992

Year

Stacey L. Berg, Frank M. Balis, Solomon Zimm, Robert F. Murphy, John S. Holcenberg, Junya Sato, Gregory H. Reaman, P. Steinherz, Andy Gillespie, Karen A. Doherty
Journal of Clinical Oncology

Abstract

Intrathecal AZQ is safe, well tolerated, and highly active against refractory meningeal malignancies.

References

YearCitations

Page 1